Immune modulatory effects of oncogenic KRAS in cancer.

Nat Commun · 2020 · PMC7595113 · PMID 33116132

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

For example, the combination of ruxolitinib with capecitabine showed a trend of improved survival in patients with metastatic pancreatic cancer and evidence of systemic inflammation 92 .

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.